18. 脊髄小脳変性症(多系統萎縮症を除く。) Spinocerebellar degeneration Clinical trials / Disease details


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01493973
(ClinicalTrials.gov)
January 201315/12/2011Efficacy Study of Epoetin Alfa in Friedreich AtaxiaA Double-blind, Randomized, Placebo-controlled, Clinical Trial to Test the Efficacy of Epoetin Alfa on Physical Performance of Friedreich Ataxia Patients.Friedreich AtaxiaDrug: Epoetin alfa;Drug: PlaceboFederico II UniversityFriedreich's Ataxia Research Alliance;Associazione Italiana per la lotta alle Sindromi Atassiche (AISA)Completed12 YearsN/ABoth56Phase 2Italy
2EUCTR2011-006156-37-IT
(EUCTR)
10/07/201226/07/2012Erythropoieitn in Friedreich AtaxiaA double-blind, randomized, placebo-controlled, clinical trial to test the efficacy of Epoetin alfa on physical performance of Friedreich Ataxia patients. - FRIEMAX FRIEDREICH ATAXIA
MedDRA version: 14.1;Level: PT;Classification code 10008025;Term: Cerebellar ataxia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: EPREX*1SIR 40000UI/ML 1ML
INN or Proposed INN: EPOETIN ALFA
Trade Name: EPREX*1SIR 10000UI 1ML
INN or Proposed INN: EPOETIN ALFA
Trade Name: BINOCRIT*1SIR 40000UI/1ML
INN or Proposed INN: EPOETIN ALFA
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO IINULLNot RecruitingFemale: yes
Male: yes
Phase 2Italy
3EUCTR2008-000040-13-AT
(EUCTR)
11/02/200927/01/2009Effects of recombinant human Erythropoietin on circulating and intramuscular endothelial progenitor cells, neovascularisation and oxidative metabolism of skeletal muscle in Friedreich’s AtaxiaEffects of recombinant human Erythropoietin on circulating and intramuscular endothelial progenitor cells, neovascularisation and oxidative metabolism of skeletal muscle in Friedreich’s Ataxia Friedreich's ataxia (FRDA) is the most common autosomal recessive neurodegenerativ disease (1:50 000) affecting the central and peripheral nervous system. Extraneural organs are also affected during the course of the disease as a significant proportian of patients develop cardiomyopathy or diabetes. FRDA is caused by a GAA triplet expansion in the FRDA gene on chromosome 9q13 resulting in a loss of function of the gene product Frataxin.Trade Name: Neorecormon
Product Name: Neorecormon
Product Code: EU1/97/031-032
INN or Proposed INN: H-116PI-DE.pdf
Other descriptive name: Epoeitin beta
Medizinische Universität Innsbruck, Univ.-Klinik für NeurologieNULLNot RecruitingFemale: yes
Male: yes
7Phase 2Austria
4EUCTR2007-003357-85-IT
(EUCTR)
10/10/200709/11/2007Randomized placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in adult patients with Friedreich's ataxia (a pilot study) - NDRandomized placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in adult patients with Friedreich's ataxia (a pilot study) - ND Friedreich ataxia (FRDA) is a rare autosomal recessive neurodegenerative disorder caused a mutation in the FXN gene, which encodes a protein named frataxin. As a result of the mutation, frataxin is quantitatively reduced but qualitatively normal. Thus, any pharmacological agent able to increase frataxin intracellular levels would have a great therapeutic relevance.
MedDRA version: 6.1;Level: PT;Classification code 10003591
Trade Name: EPREX*1FL 40000UI/ML 1ML
INN or Proposed INN: Erythropoietin
Other descriptive name: Erythropoietin
ISTITUTO NEUROLOGICO CARLO BESTANULLNot RecruitingFemale: yes
Male: yes
Italy